EUR 24.53
(10.37%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 202 Million USD | -78.71% |
2022 | 949 Million USD | -34.14% |
2021 | 1.44 Billion USD | 2997.13% |
2020 | 46.52 Million USD | 0.0% |
2019 | - USD | 100.0% |
2018 | -172.99 Million USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 295 Million USD | 46.04% |
2024 Q2 | 399 Million USD | 35.25% |
2023 Q1 | 732 Million USD | -22.87% |
2023 Q3 | 487 Million USD | -31.89% |
2023 Q2 | 715 Million USD | -2.32% |
2023 FY | 202 Million USD | -78.71% |
2023 Q4 | 202 Million USD | -58.52% |
2022 Q4 | 949 Million USD | -54.31% |
2022 Q3 | 2.07 Billion USD | 8.12% |
2022 Q2 | 1.92 Billion USD | -1.08% |
2022 FY | 949 Million USD | -34.14% |
2022 Q1 | 1.94 Billion USD | 34.77% |
2021 Q1 | 494 Million USD | 961.75% |
2021 Q3 | 965 Million USD | 50.08% |
2021 Q4 | 1.44 Billion USD | 49.33% |
2021 FY | 1.44 Billion USD | 2997.13% |
2021 Q2 | 643 Million USD | 30.16% |
2020 Q4 | 46.52 Million USD | 106.72% |
2020 Q2 | -354.91 Million USD | 0.0% |
2020 Q1 | - USD | 100.0% |
2020 FY | 46.52 Million USD | 0.0% |
2020 Q3 | -691.96 Million USD | -94.97% |
2019 Q2 | -27.07 Million USD | 15.14% |
2019 FY | - USD | 100.0% |
2019 Q4 | -25.8 Million USD | 0.0% |
2019 Q3 | - USD | 100.0% |
2019 Q1 | -31.9 Million USD | 81.56% |
2018 Q3 | 831 Thousand USD | 0.0% |
2018 FY | -172.99 Million USD | 0.0% |
2018 Q4 | -172.99 Million USD | -20917.09% |
2017 Q4 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2016 FY | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
BioNTech SE | 357.7 Million EUR | 43.528% |
CureVac N.V. | 24.82 Million EUR | -713.812% |
Biotest Aktiengesellschaft | 419.1 Million EUR | 51.801% |
Biotest Aktiengesellschaft | 419.1 Million EUR | 51.801% |
BRAIN Biotech AG | 9.72 Million EUR | -1976.907% |
Formycon AG | 467 Thousand EUR | -43154.818% |
Heidelberg Pharma AG | 10.48 Million EUR | -1826.049% |
Medigene AG | 1.00 EUR | -20199999900.0% |